Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

Table 1 Baseline characteristics

	Total	CPT-11	GEM	DDP+5-FU	P value
	(n = 107)	(n = 24)	(n = 24)	(n = 59)	OS	PFS
Mean age ± SD (yr)	57.0 ± 11.0	61.0 ± 8.7	57.5 ± 12.4	56.0 ± 11.4
Sex (M:F)	95:12	22:2	24:0	49:10
HBV
Absent/Present	26/81	7/17	6/18	13/46	0.583	0.734
Cirrhosis of the liver
Absent/Present	45/62	13/11	6/18	26/33	0.003	0.011
Tumor maximal diameter (cm)	7.8 ± 4.1	8.0 ± 3.9	7.7 ± 4.1	7.4 ± 4.2
≤ 5/> 5	30/77	4/20	5/19	21/38	0.361	0.165
Pathological T
T1/T2/T3/T4	8/32/50/17	3/8/10/3	0/9/10/5	5/15/30/9	0.070	0.052
Pathological Stage
I/II/III/IV	7/26/57/17	3/6/10/5	0/6/13/5	4/14/34/7	0.013	0.022
TACE Sessions
≤ 2/> 2	73/34	8/16	18/6	47/12	0.001	0.009
Initial AFP (ng/dL)
≤ 400/> 400	59/48	18/6	11/13	16/43	0.095	0.157
Number of Tumor Single/Multiple	57/50	12/12	13/11	32/27	0.017	0.039
Vascular invasion
Absent/Present	74/33	18/6	15/9	41/18	0.014	0.090
Child-Pugh
A/B	98/9	20/4	23/1	55/4	0.746	0.930
BCLC Stage
A/B/C	15/59/33	2/16/6	1/14/9	12/29/18	0.005	0.006
CLIP Score
≤ 2/> 2	77/20	20/4	18/6	39/20	0.013	0.013
MELD Score
≤ 6/> 6	74/33	17/7	16/8	41/18	0.914	0.610
ALB (g/L)
≤ 40/> 40	49/58	9/15	7/17	33/26	0.033	0.073
TB (μmol/L)
≤ 17/> 17	55/52	14/10	12/12	29/30	0.440	0.808
AST (U/L)
≤ 40/> 40	23/84	8/16	8/16	7/52	0.947	0.958
ALT (U/L)
≤ 40/> 40	32/75	11/13	8/16	13/46	0.456	0.522
Lipiodol (mL)
≤ 10/> 10	62/45	11/13	15/9	36/32	0.997	0.369

Exp(B) stands for relative risk (RR). M: Male; F: Female; MELD: Model for End-stage Liver Disease; BCLC: Barcelona Clinic Liver Cancer Group; CLIP: Cancer of the Liver Italian Program; ALB: Albumin; TACE: Transarterial chemoembolization; CPT-11: Chemotherapeutic agent irinotecan; GEM: Gemcitabine; 5-FU: 5-fluorouracil oxalate; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BCLC: Barcelona Clinic Liver Cancer; OS: Oxidative stress.